Contact

Location: VA 512C

Department

Pulmonary/Critical Care Medicine

Jorge Villalpando, MD

Alumni (Fellow)

Personal Statement:

I was born and raised in Monterrey, Mexico. I went to Medical school on my hometown and moved to San Antonio on 2015 to do pharmaceutical research. Meanwhile I completed my preparation to apply for internal medicine residency.


Education

Residency: UT Health San Antonio
Medical School: Universidad de Monterrey, Mexico

Training:
Training
July 2016-June 2019: Internal Medicine Residency. UT Health San Antonio
Jully 2019-June 2022: Pulmonary and Critical Care Fellowship. UT Health San Antonio

Research

Pulmonary hypertension, lung transplant and cystic fibrosis. November 2020-present: Villalpando J.,Estrada R., Restrepo M. Validating the new ATS/IDSA guidelines recommendations for the treatment of severe CAP to improve antibiotic stewardship. Division of Pulmonary and Critical Care Medicine at the South Texas Veterans Health Care System San Antonio, Texas.   March 2018-present: Restrepo M., Estrada R., Villalpando J., Villafuerte D. Vancomycin utilization and appropriateness of use in tertiary care and medical intensive care unit. Division of Pulmonary and Critical Care Medicine at the South Texas Veterans Health Care System San Antonio, Texas.   December 2017Mice model for S. pneumoniae infection. Worked on a lab model with infected mice to establish how the infection affects the lung and heart.Marcos Restrepo, MD. Division of Pulmonary & Critical Care Medicine and The South Texas Veterans Health Care System San Antonio, Texas.  Postdoctoral fellowship at Bandera Family Health Care Research  SPIRE: Studies of PCSK9 Inhibition and the reduction of vascular events- SPIRE 1 & SPIRE 2  Ramon Reyes, MD. Bandera Family Heath Care Research Department  April 2015-May2016  Funding: Pfizer, Inc.   Brief description: The primary objective of this clinical trials is to demonstrate the superior efficacy of bococizumab compared with placebo in reducing the risk of major cardiovascular events in high risk patients.   SPIRE LDL- Studies of PCSK9 inhibition and the reduction of vascular events-LDL  Ramon Reyes, MD. Bandera Family Heath Care Research Department  April 2015-May2016   Funding: Pfizer, Inc.   Brief description: The primary objective of this clinical trial is to demonstrate a superior LDL-C lowering effect of bococizumab compared to placebo in patients with primary hyperlipidemia or mixed dyslipidemia at risk of cardiovascular events receiving a maximally tolerated dose of statin.  REDUCE-IT (reduction of cardiovascular events with EPA- intervention trial)  Ramon Reyes, MD. Bandera Family Heath Care Research Department  April 2015-May2016  Funding: Amarin Pharma Inc.  Brief description: The primary objective of this clinical trial is to evaluate the effect of EPA for preventing the occurrence of first major cardiovascular event in patients at LDL-C goal while on statin therapy with established cardiovascular disease or at high risk of cardiovascular disease and hypertriglyceridemia.  Achieve Control Life Study Program (Sanofi LPS 14347)  Ramon Reyes, MD. Bandera Family Heath Care Research Department  June 2015-May2016  Funding: Sanofi U.S., Inc.  Brief Description: The primary objective of this clinical trial is to demonstrate the benefit of Toujeo / insulin glargine 300 units/ml- in achieving individualized HbA1c targets without documented symptomatic hypoglycemia from baseline to 6 months in uncontrolled insulin naïve patients with T2DM initiating basal insulin therapy in a real world setting. 

Awards & Accomplishments

May 2019: ATS Resident to Fellow Bootcamp Scholarship. Awarded with scholarship to attend the annual ATS bootcamp for incoming national and international Pulmonary Critical Care Fellows.  

Affiliations

Board certifications American Board of Internal Medicine 2019   Society Memberships American Medical Association American College of Physicians American Thoracic Society American College of Chest Physicians Society of Critical Care Medicine  

News

Research experience March 2018-present: Estrada R., Villalpando J., Villafuerte D., Anzueto A., Restrepo M., et al. Vancomycin utilization for Community-Acquired Pneumonia Patients Admitted to MICU. The University of Texas Health at San Antonio, South Texas Veterans Health Care System.   Postdoctoral fellowship at Bandera Family Health Care Research: Worked on several clinical trials in charge of data collection and entry, reviewed charts to identify potential candidates. Assisted the attending physician during follow up visits for possible medication side effects and scheduled physicals. SPIRE: Studies of PCSK9 Inhibition and the reduction of vascular events- SPIRE 1 & SPIRE 2 Ramon Reyes, MD. Bandera Family Heath Care Research Department April 2015-May2016 Funding: Pfizer, Inc.

Publications

Educational papers November 2017: Sandra G. Adams, MD, MS, Jorge Villalpando, MD, Haritha Saikumar, MD, Donghwan Lee. A Basic Guide for Interpreting Spirometry. UT Health San Antonio, Division of Pulmonary & Critical Care Medicine and The South Texas Veterans Health Care System San Antonio, Texas. Submitted papers February 2013: . Vincenzo Sabella, MD; Jorge Villalpando; Jesus David Gonzalez-Lugo.  Robotic-assisted laparoscopic cerclage in pregnant and non-pregnant patients: preliminary report of 18 cases. Journal of minimally invasive gynecology Published papers Villalpando J, Peters JI, Adams SG. Inducible Laryngeal Obstruction/Vocal Cord Dysfunction and the Role It Plays in Refractory Asthma. Arch Asthma Allergy  Immunol. 2017; 1: 036-039.